Cargando…

Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19

The repurposing of colchicine for the treatment of COVID-19 was suggested based in its immunomodulatory, anti-inflammatory, and anti-viral properties. We performed a single-center propensity score matched cohort study, including all consecutive COVID-19 patients admitted to a community hospital betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunetti, Luigi, Diawara, Oumou, Tsai, Andrew, Firestein, Bonnie L., Nahass, Ronald G., Poiani, George, Schlesinger, Naomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565543/
https://www.ncbi.nlm.nih.gov/pubmed/32937800
http://dx.doi.org/10.3390/jcm9092961
_version_ 1783595956915142656
author Brunetti, Luigi
Diawara, Oumou
Tsai, Andrew
Firestein, Bonnie L.
Nahass, Ronald G.
Poiani, George
Schlesinger, Naomi
author_facet Brunetti, Luigi
Diawara, Oumou
Tsai, Andrew
Firestein, Bonnie L.
Nahass, Ronald G.
Poiani, George
Schlesinger, Naomi
author_sort Brunetti, Luigi
collection PubMed
description The repurposing of colchicine for the treatment of COVID-19 was suggested based in its immunomodulatory, anti-inflammatory, and anti-viral properties. We performed a single-center propensity score matched cohort study, including all consecutive COVID-19 patients admitted to a community hospital between 1 March 2020 and 30 May 2020. Patients were stratified according to the receipt of colchicine. The primary endpoint was defined as in-hospital death within 28-days follow-up. Secondary endpoints included favorable change in the Ordinal Scale for Clinical Improvement on days 14 and 28 versus baseline, proportion of patients not requiring supplemental oxygen on days 14 and 28, and proportion of patients discharged by day 28. In total data for 303 PCR positive COVID-19 patients were extracted and 66 patients were included in the 1:1 matched cohort study. At the end of the 28 day follow-up, patients receiving colchicine were approximately five times more likely to be discharged (odds ratio, 5.0; 95% confidence interval, 1.25–20.1; p = 0.023) and when comparing mortality, there were 3 deaths (9.1%) in patients receiving colchicine versus 11 deaths (33.3%) in the groups receiving standard of care (odds ratio, 0.20; 95% confidence interval, 0.05–0.80; p = 0.023). These observations warrant further investigation in large controlled clinical trials.
format Online
Article
Text
id pubmed-7565543
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75655432020-10-26 Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19 Brunetti, Luigi Diawara, Oumou Tsai, Andrew Firestein, Bonnie L. Nahass, Ronald G. Poiani, George Schlesinger, Naomi J Clin Med Article The repurposing of colchicine for the treatment of COVID-19 was suggested based in its immunomodulatory, anti-inflammatory, and anti-viral properties. We performed a single-center propensity score matched cohort study, including all consecutive COVID-19 patients admitted to a community hospital between 1 March 2020 and 30 May 2020. Patients were stratified according to the receipt of colchicine. The primary endpoint was defined as in-hospital death within 28-days follow-up. Secondary endpoints included favorable change in the Ordinal Scale for Clinical Improvement on days 14 and 28 versus baseline, proportion of patients not requiring supplemental oxygen on days 14 and 28, and proportion of patients discharged by day 28. In total data for 303 PCR positive COVID-19 patients were extracted and 66 patients were included in the 1:1 matched cohort study. At the end of the 28 day follow-up, patients receiving colchicine were approximately five times more likely to be discharged (odds ratio, 5.0; 95% confidence interval, 1.25–20.1; p = 0.023) and when comparing mortality, there were 3 deaths (9.1%) in patients receiving colchicine versus 11 deaths (33.3%) in the groups receiving standard of care (odds ratio, 0.20; 95% confidence interval, 0.05–0.80; p = 0.023). These observations warrant further investigation in large controlled clinical trials. MDPI 2020-09-14 /pmc/articles/PMC7565543/ /pubmed/32937800 http://dx.doi.org/10.3390/jcm9092961 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Brunetti, Luigi
Diawara, Oumou
Tsai, Andrew
Firestein, Bonnie L.
Nahass, Ronald G.
Poiani, George
Schlesinger, Naomi
Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
title Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
title_full Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
title_fullStr Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
title_full_unstemmed Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
title_short Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
title_sort colchicine to weather the cytokine storm in hospitalized patients with covid-19
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7565543/
https://www.ncbi.nlm.nih.gov/pubmed/32937800
http://dx.doi.org/10.3390/jcm9092961
work_keys_str_mv AT brunettiluigi colchicinetoweatherthecytokinestorminhospitalizedpatientswithcovid19
AT diawaraoumou colchicinetoweatherthecytokinestorminhospitalizedpatientswithcovid19
AT tsaiandrew colchicinetoweatherthecytokinestorminhospitalizedpatientswithcovid19
AT firesteinbonniel colchicinetoweatherthecytokinestorminhospitalizedpatientswithcovid19
AT nahassronaldg colchicinetoweatherthecytokinestorminhospitalizedpatientswithcovid19
AT poianigeorge colchicinetoweatherthecytokinestorminhospitalizedpatientswithcovid19
AT schlesingernaomi colchicinetoweatherthecytokinestorminhospitalizedpatientswithcovid19